ArticleThe New England journal of medicine2012
RAF around the edges--the paradox of BRAF inhibitors.
Article in The New England journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- BRAF Inhibition-Associated Nuclear Remodeling is Linked to Cancer-Associated Fibroblast Activation.Cancer research communications · 2026Article
- Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton's tyrosine kinase inhibitor.JAAD case reports · 2024Article
- Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study.Journal of clinical medicine · 2023Article
- A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced PretreatedCancers · 2021Article
- Adult pilocytic astrocytoma in the molecular era: a comprehensive review.CNS oncology · 2021Review
- Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.Expert review of precision medicine and drug development · 2021Article
- Activation by substoichiometric inhibition.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Complete regression of primary melanoma associated with nevi involution under BRAF inhibitors: A case report and review of the literature.Oncology letters · 2019Article
- Cutaneous toxicities of new treatments for melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Mps1 is associated with the BRAFOncology letters · 2018Article
- Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.Oncogenesis · 2017Article
- Melanoma in congenital melanocytic naevi.The British journal of dermatology · 2017Review
- LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.Oncotarget · 2017Article
- Vemurafenib-induced progression of breast cancer: a case report and review of the literature.Targeted oncology · 2016Review
- Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.Targeted oncology · 2016Article
- Article
- Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.International journal of nanomedicine · 2015Article
- Toward personalized cancer nanomedicine - past, present, and future.Integrative biology : quantitative biosciences from nano to macro · 2013Article
- Hairy cell leukemia in kidney transplantation: lesson from a rare disorder.Experimental hematology & oncology · 2013Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22256810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.